A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease ...

Results from a phase 3 trial presented today showed that patients treated with Lynparza (olaparib) had a 42% reduction in risk of their disease worsening or death in for patients with HER2 ...

AZ and Merck said that the approval makes Lynparza (olaparib) the only PARP inhibitor to have shown an improvement in overall survival when used in this setting, ahead of rivals like Clovis ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses Lynparza’s role in reducing the risk of invasive disease recurrence or death in HR-positive breast cancer patients.

Targeted therapies for HER2-negative advanced breast cancer include: PARP inhibitors like olaparib (Lynparza) and talazoparib (Talzenna). These drugs stop a protein known as poly-ADP ribose ...

Olaparib (Lynparza, AstraZeneca) is indicated as 'monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2 negative locally advanced or metastatic breast cancer.

New Delhi: The Drug Controller General of India (DCGI), Rajeev Raghuvanshi, has directed state authorities to withdraw AstraZeneca’s Olaparib Tablets, 100mg and 150mg, due to potential adverse ...

Olaparib - which is also known under the brand name Lynparza - was approved for prescription to adults with breast cancer linked to the BRCA1 gene, or those with mutated HER2-negative advanced ...